Boehringer Ingelheim and Ashoka announce a global partnership for "Making More Health"

Boehringer IngelheimBoehringer Ingelheim and Ashoka will launch a three-year global initiative to improve health in communities around the world.The "Making More Health" initiative will promote healthy individuals, families and communities by identifying and supporting the most promising solutions to challenge health problems.

The partnership includes support for a series of programs aimed at identifying innovative health solutions, including the election of 50 leading social entrepreneurs (elected as "Ashoka Fellows") whose ideas are driving cutting-edge systemic solutions in the field of health. In addition, two web-based changemakers competitions will open an invitation to the public to submit new ideas on how to improve health in underserved communities. "Making More Health" will also focus on the next generation of changemakers through a youth venture program to engage young people in designing health solutions for their communities.

Boehringer Ingelheim will support "Making More Health" by engaging its 42,000 employees worldwide in various capacities to help spread an understanding and appreciation of social entrepreneurship and health innovation within their own communities.

Boehringer Ingelheim will support "Making More Health" by engaging its 42,000 employees worldwide in various capacities to help spread an understanding and appreciation of social entrepreneurship and health innovation within their own communities.

"Making More Health brings together two organizations committed to finding innovative people and ideas to help shape the future of the health sector," said Professor Dr Andreas Barner, chairman of the board of managing directors at Boehringer Ingelheim. "Through this partnership we will bring forth meaningful and sustainable solutions that can achieve individual and family well-being in communities around the globe."

Ashoka's Chair, Bill Drayton, commented: "Some parts of how the world deals with health are highly creative, most especially the development of new pharmaceuticals, an area where Boehringer Ingelheim has made contribution after contribution for 125 years. Much of the rest of the system, however, has fallen way behind the need. The Making More Health partnership creates a global and business/social alliance led by top entrepreneurs and open to all that we believe will bring big changes to the entire system."

To date, "Making More Health" has supported four leading Ashoka social entrepreneurs in the health sector, including Rebecca Onie, founder of Health Leads in the United States; Frank Hoffmann, founder of Discovering Hands in Germany; Guillaume Bapst, founder of ANDES in France; and Luh Ketut Suryani, founder of the Suryani Institute for Mental Health in Indonesia.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

About Ashoka
Ashoka is the global association of the world's leading social entrepreneurs—men and women with system changing solutions for the world's most urgent social problems. Since 1981, Ashoka has helped launch over nearly 3000 leading social entrepreneurs as Ashoka Fellows, providing them with living stipends, professional support, and access to a global network of peers in 70 countries. Ashoka is known around the world for launching the field of social entrepreneurship and its current work in creating an "Everyone a Changemaker" world encouraging innovation and problem-solving from all.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...